secwatch.observer — SEC 8-K summary
======================================

Issuer:     USANA HEALTH SCIENCES INC (USNA)
CIK:        0000896264
Form:       8-K
Filed at:   2026-10-05T20:36:30+00:00
Accession:  0000896264-26-000060
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

USANA amends $75M credit facility, sets $100M minimum EBITDA covenant and allows Sydney property sale
--------------------------------------------------------------------------------

- USANA entered a First Amendment to its June 27, 2025 credit agreement on Sept. 30, 2026, with Bank of America as administrative agent.
- The $75,000,000 revolving facility matures June 27, 2030 and may be increased by up to $200,000,000 upon request.
- Minimum Consolidated EBITDA covenant is $100,000,000 for trailing four quarters, dropping to $70,000,000 if aggregate revolving exposure is $50,000,000 or less.
- Annual general asset sale basket rises from $500,000 to $2,500,000; new clause permits USANA Australia Pty, Ltd to sell Sydney real property.
- Sale-leaseback transactions remain prohibited except as agreed by Required Lenders or if tied to the Sydney disposition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/896264/000089626426000060/0000896264-26-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/896264/000089626426000060/usna-20261005.htm
  HTML page:      https://secwatch.observer/filing/0000896264-26-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer